Kornimate/medical-research-clean huggingface dataset:
prevalence of ocular surface disease in malaysian glaucoma patients

Conditions: Primary Open-angle Glaucoma; Primary Angle-Closure Glaucoma; Pseudoexfoliation Glaucoma; Pigment Dispersion Glaucoma; Ocular Hypertension

Summary: this is a prospective, multi-centre, cross sectional observational study to determine the prevalence of ocular surface disease (osd) in glaucoma patients, nationwide. the study also analyses sub group of osd prevalence, stratified according to the treatment types (i.e. preserved, preservative-free, and combination of preservative-free and preserved eyedrops), and illustrates the patient perspective on osd.

for this prospective, multi-centre, cross sectional observational study, patients who attend routine eye examination at the medical institutions and who have been diagnosed with primary open-angle glaucoma, primary angle-closure glaucoma, pseudoexfoliation glaucoma, pigment dispersion glaucoma or ocular hypertension will be studied. the medical institutions are selected across different regions of malaysia to assess the nationwide prevalence of osd in glaucoma patients. the routine assessments include corneal evaluation, tear break-up time (tbut), hyperemia and schirmer's test whereby the data from these assessments will be collected and analyzed. the study will also includes symptom evaluation and questionnaire feedback.

Eligibility criteria:
inclusion criteria: * 1) age of 21 years or older and those who can provide informed consent. * 2) on anti-glaucoma medications for \>6 months * 3) iop ≤ 21 mm hg in the study eye at the screening examination (under treatment) * 4) if only one eye is eligible, it is to be evaluated. if both eyes are eligible, then the eye with a higher nei score will be selected for evaluation. * 5) a best-corrected visual acuity score of 6/36 on the snellen chart, or better in each eye. exclusion criteria: * 1) those with secondary ocular hypertension or glaucoma * 2) those with severe visual field disorder (mean deviation of 20 db or worse) * 3) those with a history of ocular surgeries (intraocular surgery including ocular laser treatment which may affect the patient's ocular surface condition) within 6 months prior to the study initiation. * 4) those with a history of glaucoma surgery * 5) those with a history of corneal refractive surgery * 6) those with severe dry eye associated with systemic disorders, or in need of drugs to treat dry eye * 7) those with ocular allergy, ocular infection or ocular inflammation * 8) those using eye drops for other ocular comorbidities * 9) those who need to use systemic or ophthalmic steroids (excluding topical skin steroidal ointment) * 10) female patients who are pregnant, nursing or lactating * 11) those who use contact lenses * 12) any corneal abnormality or other corneal comorbidity condition preventing reliable applanation tonometry * 13) those on oral antihistamine, antipsychotic or anti-depressant drugs.
prazosin use in adults with anxiety disorders

Conditions: Anxiety; Anxiety Disorders

Summary: prazosin has shown effectiveness in treating post-traumatic stress disorder through improving sleep quality and global functioning. given the significant evidence for its utility in treating ptsd, in combination with the fact that many anxiety symptoms overlap with ptsd (e.g.insomnia, hyperarousal, and irritability), it is essential to evaluate its potential effectiveness in treating symptoms of other anxiety disorder and patient tolerability.


Eligibility criteria:
inclusion criteria: 1. existing diagnosis of any anxiety disorder according to dsm-5 criteria (i.e. gad, panic disorder, agoraphobia, social phobia or specific phobias) 2. newly diagnosed patients or patients who are either resistant or not adherent to their current treatment are eligible to be enrolled in the study. 3. if patient is on anti-hypertensive therapy, the dose of anti-hypertensive(s) must be stable for at least 4 weeks prior to the study and blood pressure must be well controlled. exclusion criteria: 1. patients with comorbid condition of psychosis, a diagnosis of ptsd, an active severe substance use disorder, or actively suicidal. 2. patients actively enrolled in psychotherapy sessions at the time of the study. 3. patients experiencing baseline systolic blood pressure ≤100 mmhg supine, orthostatic hypotension (a decrease in systolic blood pressure from a sitting position of 20 mmhg or more after 2 minutes standing accompanied with light-headedness), or a baseline diastolic blood pressure less than 60 mmhg. 4. pregnant or lactating women. 5. patients with acute medical or psychiatric conditions that require immediate hospital admission. 6. patients with a history of allergic reaction to prazosin or any of its components. 7. patients unable to communicate in english. 8. patients who are scheduled to undergo cataract surgery are excluded from the study until after the surgery has been completed.
randomized, multicenter, 2-dose level. open-label, phase iia study with the intraperitoneally infused trifunctional bispecific antibody removab(tm) (anti-epcam x anti-cd3) to select the better dose level in platinum refractory epithelial ovarian cancer patients

Conditions: Ovarian Cancer; Fallopian Tube Neoplasms; Peritoneal Neoplasms

Summary: patients with epithelial ovarian cancer, fallopian tube or peritoneal cancer who receive surgical cytoreduction and platinum/taxane containing chemotherapy have a significant chance of entering complete clinical remission but about 70% will eventually relapse. many patients respond to additional cytotoxic treatment with partial or complete responses, yet approximately 100% of these patients will ultimately progress. novel consolidation strategies following treatment for recurrent disease are needed and an immunologic approach is an attractive option.epcam is expressed in a large number of epithelial ovarian cancer, fallopian tube or peritoneal cancer tissues. thus targeting these cancers with an anti-epcam antibody is a promising innovative therapeutic approach.


Eligibility criteria:
inclusion criteria: women 18 years and older histologically confirmed epithelial ovarian cancer, cancer of the fallopian tube or peritoneum measurable disease signed and dated informed consent one or two prior chemotherapies, the last platinum containing platinum refractory disease ecog performance status 0-2 exclusion criteria: acute or chronic infections previous treatment with mouse monoclonal antibodies known or suspected hypersensitivity to removab inadequate renal function inadequate hepatic function ileus cachectic patients

Keywords: cancer cancer alternative therapies ovarian cancer
biomechanical changes after trabeculectomy

Conditions: Glaucoma, Primary

Summary: corneal biomechanics are studied in glaucoma patients prior and at least 6 month after trabeculectomy.

prior to trabeculectomy corneal biomechanics are measured with the ocular response analyzer (ora, reichert) and the corvis st (oculus). both instruments work with an air-puff which deforms the cornea. intraocular pressure is measured like in non-contact air-puff tonometry. the ora also measures corneal hysteresis (ch) and the corneal resistance factor (crf) which are qualitative measures of corneal biomechanics. the corvis is a high-speed scheimpflug-camera (4330 frames/sec) that records the quantitative movements of the cornea. at least 6 month after uncomplicated trabeculectomy the measurements are repeated.

Eligibility criteria:
inclusion criteria: * glaucoma patients in need of further iop-reduction despite maximally tolerated therapy and assigned for trabeculectomy. minimum of 18 years. exclusion criteria: * corneal pathologies.

Keywords: open angle glaucoma corneal biomechanics trabeculectomy
to compare the efficacy and safety of carvedilol with or without simvastatin in patients with portal hypertension and esophageal varices.

Conditions: Cirrhosis With Esophageal Varices

Summary: after successful screening of patients based on inclusion criteria, we will measure the baseline hepatic venous pressure gradient. at day 1 patients will undergo complete blood investigation including complete haemogram, kidney function test, liver function test, prothrombin time, afp (alfa feto protein) level, chest x ray, ultrasonography, fibroscan. routine complete physical examination will be done.


Eligibility criteria:
inclusion criteria: 1. all patients of chronic liver disease with esophageal varices. 2. age more than and equal to 18 years. exclusion criteria: 1. patients of chronic liver disease with history of upper gastro intestinal bleed. 2. patients of acute on chronic liver failure 3. thrombosis of splenoportal axis 4. hepatocellular carcinoma 5. patients who were on primary variceal ligation sessions as prophylaxis 6. patients who are beta blocker intolerant (prior h/o hypotension, bradycardia). 7. patients who are contraindicated for beta blockers {h/o copd (coronary obstructive pulmonary disease), heart block, refractory ascites, sbp(spontaneous bacterial peritonitis) , hrs(hepato renal syndrome)}. 8. failure to give consent for inclusion in the study
study of neurocognitive therapeutic exercise in the shoulder impingement syndrome in comparison with traditional therapeutic exercise

Conditions: Shoulder Impingement Syndrome

Summary: it is a single-blind randomized controlled clinical trial to evaluate the effectiveness of neurocognitive therapeutic exercise in subjects affected by shoulder impingement syndrome in comparison with traditional therapeutic exercise. the traditional exercise protocol contains mainly strengthening exercises, stretching exercises, codman's pendulum exercises and exercises against elastic band resistance. the neurocognitive exercise protocol contains ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture). each subject, randomly assigned to either neurocognitive therapeutic exercise (group 1) or traditional therapeutic exercise (group 2), will be submitted to one-hour session for three times a week for five weeks. the outcome measures used will be the quick-dash questionnaire, the constant-murley shoulder outcome score, the ases score, a visual analogic scale (vas) and the assessment will be performed at baseline (t0), at the end of treatment protocol (t1), at 3 months (t2) and 6 months (t3) from the end of treatment.


Eligibility criteria:
inclusion criteria: * subjects with shoulder impingement syndrome established by clinical examination, x-ray in anteroposterior, axillary and outlet views, and magnetic resonance imaging (mri) or echography. exclusion criteria: * rotator cuff and/or subscapularis tendon partial/full-thickness tears, * capsulolabral pathology responsive to surgical repair, * congenital abnormalities of the acromion, * previous surgery on the affected shoulder, * inflammatory or neurological (systemic or local) diseases involving shoulder girdles, * cognitive or psychiatric disorders, * local tumor metastasis or application of radiotherapy, * acute infections or osseous tuberculosis.

Keywords: conservative treatment shoulder neurocognitive therapeutic exercise traditional therapeutic exercise pain
prospective controlled study evaluating cryocontact therapy of infantile hemangiomas of preterm infants

Conditions: Hemangioma of Preterm Infants

Summary: prospective controlled study evaluating cryocontact therapy of infantile hemangiomas of preterm infants principal investigator: rangmar goelz, md coworkers: m möhrle, m moll, hm häfner, w schippert, c meisner, m röcken, cf poets background despite their frequent occurrence, there is no established therapeutic procedure for localized infantile hemangioma in preterm infants. a pubmed search with the key words hemangioma, controlled study, infant or childhood revealed five studies (1-5), none of them included preterm infants, even though low birth weight and prematurity have been described as the most significant risk factors aim: to evaluate cryocontact therapy of infantile hemangioma (ih) of 1 - 10 mm diameter in preterm infants \<=34 weeks of gestational age (ga) using a liquid nitrogen cooled metal at the department of neonatology at the tuebingen university hospital. method: in a prospective controlled study, preterm infants \<= 34 weeks ga with at least 2 ih should be randomized to have one treated with cryocontact therapy using a liquid nitrogen cooled metal (-196°c), while the other one is left untreated. primary endpoint is an intact skin at the site of the hemangioma at 1 year corrected age . the study starts at august 1st, 2004. cryocontact is done by 3 trained dermatologist (mm, hmh, ws), outcome documentation, including photodocumentation, by 2 neonatologist (rg, momo). statistical analysis: a sample size of 25 intrapersonal pairs of treated and untreated ih is needed to show a significant difference with alpha=0.05 and beta=0.9 between treated ih and controls, assuming that 5% of the treated ih and 40% of the controls have an unsuccessful primary outcome. documentation will be made on standardized forms and the data will be transferred to excel. biometric calculations will be handled with sas 9.1.3. for windows using fisher´s exact test for difference in proportions. ethics: the study is approved by the ethics committee of tuebingen university hospital; all parents must give written informed consent.


Eligibility criteria:
inclusion criteria: * preterm infants \<=34 weeks ga with hemangioma exclusion criteria: * no hemangioma
wheat bread study: comparison of the tolerance of different wheat breads

Conditions: Non-celiac Gluten Sensitivity; Wheat Hypersensitivity

Summary: this study aims to assess the differences in tolerability of differently manufactured wheat breads in a target group of individuals with suspected wheat sensitivity. additionally, it will be verified, if the absence of a response to oral exposure to defined bread types is associated with an absence of mucosal changes following cle-assisted mucosal provocation with bread.

nowadays, more than 20% of people in industrialized countries suffer from a food intolerance or food allergy, with wheat and gluten intolerances on the rise. besides the well-known conditions celiac disease and wheat allergy, another clinical entity called non-celiac wheat sensitivity (ncws) was described, which is not yet widely understood. resulting from inconsistent diagnostic criteria the prevalence of ncws varies from 0.5% to 13%. due to the lack of validated diagnostic criteria and/or appropriate biomarkers for diagnosis of ncws, it can currently only be suspected by exclusion of other diseases. to verify suspected ncws, a double-blind placebo-controlled food challenge with wheat is recommended. a confocal laser endomicroscopy (cle) with endoluminal provocation can also provide meaningful results on the individual intestinal mucosal response to specific allergens. furthermore, it is as yet unclear whether ncws is triggered by gluten, fodmaps, or other wheat components such as α-amylase trypsin inhibitors. bread manufacturing processes can influence the composition of bread and the presence of possible triggers of intolerance reactions. this study aims to investigate the tolerability of differently manufactured wheat breads in individuals with suspected ncws. additionally, we expect this approach to improve the currently inadequate diagnosis of ncws, as well as to provide a better understanding of the underlying mechanisms. therefore, individuals with suspected ncws are included in the trial. five different types of bread will be tested, including 3 differently manufactured wheat breads, a gluten free bread and a gluten free bread with added wheat flour. aim of this part is to test a possible psychological factor in ncws symptoms.

Eligibility criteria:
inclusion criteria: * age ≥18 ≤75 years * signed declaration of consent * willingness to adhere to the prescribed diet for the duration of the study * chronic gastrointestinal symptoms for at least 6 months * anamnestic wheat sensitivity * no acute or chronic gastrointestinal diseases (e.g. celiac disease / wheat allergy) * no or stable medication for at least 3 months * no participation in another clinical trial (current or within the past 30 days) exclusion criteria: * taking intestinal therapeutics, antibiotics, immunosuppressants, anti-allergic medication or similar * pregnancy / lactation * occurrence of relevant diseases (possibly individual decision) * revocation of consent * concurrent participation in another clinical study

Keywords: human nutrition ncws wheat bread cle
cognition and gut microbiome associated study of shanghai people with acute ischemic stroke

Conditions: Gastrointestinal Microbiome

Summary: the purpose of this study is to evaluate the effect of probiotics on the gut microbiome of ischemic stroke patients.

this study aims to detect the impact of probiotics administration during the process of ischemic stroke treatment and recovery phase. the day of admission and 3months after stroke data will be collected and put into analysis to provide some suggestions on the probiotics use in the clinical for the stroke patients.

Eligibility criteria:
inclusion criteria: * patients diagnosed with acute ischemic stroke on the basis of world health organization diagnostic criteria1. the time from paroxysm to admission ≤2weeks. exclusion criteria: * imaging diagnoses hemorrhagic stroke severe depression severe disturbance of hearing vision and reading illiteracy have recognitive disorder before stroke (recorded in medical records) treated with antibiotics probiotics or prebiotics in1month before admission

Keywords: probiotics gut microbiota ischemic stroke
early life intervention in pediatrics supported by e-health

Conditions: Adiposity; Childhood Obesity; Adolescent Obesity; Non-communicable Disease; Life Style; Behavior, Eating; Behavior, Health

Summary: childhood obesity in early life contributes to the development of specific ncds, i.e. adult obesity. unhealthy diet and low level of physical activity are lifestyle risk behaviors associated with chronic, systemic inflammation, which promotes the pathogenesis of ncds. early preventive measures to improve lifestyle behavior are of utmost importance. the aim of elipse-i is to assess whether an ehealth application intervention for parents is feasible and efficacious in lowering total energy intake/total energy expenditure (tei/tee) ratio in their children with bmi \>97 centile (elipse-i).

elipse-i represents a single-blind randomized controlled parallel-group clinical trial. in elipse-i, 148 children, matched for sex, 6-12 years of age with a bmi \>97 centile based on national growth charts will be included. children will be recruited at the children's university hospital and randomly (1:1) assigned to a control and intervention group. all participants receive treatment-as-usual (tau), parents of participants in the intervention group additionally receive a smartphone application (lifestyle app) for 20 weeks. the app aims to promote healthy behavior through cognitive-behavioral impact factors (i.e., psychoeducation, goal setting), that are applied by a psychologist via structured feedback. single-blinded assessments will be conducted at baseline, following the intervention period of 20 weeks, and at 6-month follow-up after the end of the intervention. the primary endpoint is reduction of the tei/tee ratio in children with obesity. secondary endpoints in elipse-i include lowering the severity of obesity, cardiometabolic risk factor improvement, reduction in chronic low-level inflammatory biomarkers, and improved children's quality of life. a further endpoint is acceptance and usability of the app.

Eligibility criteria:
inclusion criteria: * german speaking parents * any ethnic background/race * children should live/grow-up in the same household as the parental participant * children with an age- and sex-matched bmi \>97 centile according to swiss national growth charts * children who newly attend the outpatient weight management clinic at the division of pediatric endocrinology at the university children's hospital bern * signed informed consent form from parent(s) exclusion criteria: * syndromic obesity * known congenital disease affecting musculo-skeletal, cardiac or pulmonary function * insufficient knowledge of german language * participation in another clinical trial targeting similar objectives

Keywords: adiposity children adolescents prevention ehealth
posterior capsule opacification (pco) with single piece hydrophobic versus hydrophillic intraocular lens (iol)

Conditions: Posterior Capsule Opacification

Summary: the purpose of the study was to compare the postoperative pco results of the single-piece hydrophobic acrylic iols versus the newer generation single-piece hydrophilic acrylic iols in patients undergoing bilateral cataract surgery.

amongst several surgical techniques and iol technology that influence the opacification of the posterior capsule, the role of iol material and optic design remain crucial in determining its development. the single-piece acrylic iols with a hydrophobic surface have been widely used in practice. the single-piece acrylic iols with a hydrophilic surface became commercially available more recently. although there is a study that compared the single piece hydrophobic and the single piece hydrophilic iol, it was conducted on the older generation of the hydrophilic iol. moreover, experimental and clinical study has been performed to evaluate the posterior capsule opacification between the hydrophilic acrylic iol with a sharp optic edge design excluding the optic-haptic junction, versus the newer generation hydrophilic iol design which has an improved 360-degree sharp edge, with results favouring the latter design. there is little data that compares the single-piece acrylic iols with a hydrophobic surface to the newer generation single-piece acrylic iols with a hydrophilic surface. because the iol characteristics play a crucial role to prevent posterior capsule opacification (pco), it is of clinical importance, as well as investigational interest to assess the pco following implantation of these iols. we conducted a prospective, randomised, intra-individual study to compare the 3 year postoperative pco results of the single-piece hydrophobic acrylic iols versus the newer generation single-piece hydrophilic acrylic iols in patients undergoing bilateral cataract surgery.

Eligibility criteria:
inclusion criteria: * bilateral senile surgery * age ranged from 53 to 78 years * pupil mydriasis \> 7 mm * no history of previous ocular surgery * gave consent for followup examination exclusion criteria: * coexisting ocular morbidities * diabetes mellitus

Keywords: hydrophobic acrylic pco posterior capsule opacification hydrophilic acrylic io
impaired regulation of energy balance in elderly people (balance study)

Conditions: Anorexia of Ageing

Summary: over the past century life expectancy has risen rapidly. as a result, the proportion of elderly people continues to grow. elderly people probably have an impaired regulation of energy balance (energy intake versus energy expenditure) whereby the underlying physiological mechanisms are not fully understood. the first objective of this study is to provide further evidence for an age-related failure to regulate energy balance in elderly. if the hypothesis of impaired regulation of energy balance in elderly is confirmed then the second objective becomes to elucidate the underlying physiological mechanisms of the age-related failure to regulate energy intake in elderly.


Eligibility criteria:
inclusion criteria: * men * healthy * 20-40 and 65-85 years of age * normal weight * free-living in wageningen and surrounding exclusion criteria: * anemia * diabetes * restrained eating * dementia * weight changes of \> 2 kg during the last 2 months

Keywords: anorexia of ageing anorexia of aging energy balance elderly